Can-Fite BioPharma
Muscles Don’t Get Cancer

When Dr. Pnina Fishman discovered that cancer doesn’t attack striated muscle tissue, she knew she was onto something. So she founded Can-Fite BioPharma (NYSE MKT: CANF) and went to work using this information to develop cancer treatments.

Based on research that the Gi protein coupled A3 adenosine receptor (A3AR) is highly expressed in patients with inflammatory and cancer diseases. Targeting the receptor with Can-Fite’s compound, Namodenoson, induces anti-inflammatory and anti-cancer effects. In addition, the high A3AR receptor expression predicts patient’s positive response to drug treatment.

Can-Fite’s liver cancer drug, Namodenoson, recently completed a Phase II trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and is in a Phase II trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the FDA. It has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma.

Can-Fite has licensed Namodenoson for the treatment of Liver Cancer and NASH to Chong Kun Dang Pharmaceut in Korea and to CMS in China.

Can-Fite’s research further suggests that Namodenoson attacks diseased cells by modulating key signaling proteins which kills inflammatory and cancer cells. At the same time, normal cells are immune to the effects of the drugs since they don’t have these signaling proteins. This effect contributes significantly to the safety profile of their drugs. 

Think of it as a lock and key. Can-Fite’s drugs are keys that will only work on pathological cells, not healthy cells.

Can-Fite’s other drug candidate in the company pipeline is CF602 that has shown efficacy in the treatment of erectile dysfunction in preclinical studies. It is being prepared for an IND submission to the FDA and a Phase I trial. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical studies to date.

For more information about Can-Fite and to schedule a conversation with Dr. Fishman, please contact FORCE Family Office CEO, Steven Saltzstein.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.